好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Genome-wide Association Study of Tau PET in the Mayo Clinic Study of Aging
Aging, Dementia, and Behavioral Neurology
S4 - Aging and Dementia: Risk Factors and Genetics (2:36 PM-2:48 PM)
009
To identify genetic factors associated with tau deposition in older adults.

Tau deposition is a key biological feature of Alzheimer’s disease, but the heritable influences on susceptibility and resistance to tau deposition are not well-understood.  The recent availability of tau-PET provides an opportunity to test the hypothesis that common genetic variants would be associated with entorhinal cortex (ERC) tau burden, a sensitive marker of early tau deposition.

Inclusion criteria included individuals over age 50 from the population-based Mayo Clinic Study of Aging with genome-wide genotype and regional tau-PET (AV-1451) data.  Following genotyping with the Illumina GSA array and standard quality control, 515,206 single nucleotide polymorphisms (SNPs) were available for analysis.  A genome-wide association study of ERC tau was performed using an additive genetic model and covarying for age and sex.  Post-hoc stratified analyses utilized amyloid positivity (global PiB>1.48) as a discriminator.

The study sample included 754 individuals (mean age 72.4 years, 54.6% men, 87.4% cognitively unimpaired).  A genome-wide significant association was identified for rs75546066, in an intergenic region on chromosome 9, with the minor (A, frequency=2.7%) allele associated with lower ERC tau (p=2.85x10-8, β=-0.49), and with a stronger effect in amyloid-negative (β=-0.51) versus amyloid-positive (β=-0.23) individuals.  No associations with ERC tau burden were identified for the SNPs defining APOE (apolipoprotein E) ?4 or for genotyped SNPs previously associated with AD in large case-control studies.  Three SNPs within MAPT (microtubule-associated protein tau) displayed nominal associations to ERC tau burden, including rs3785883 (p=0.04, β=0.07) which was previously associated with higher cerebrospinal fluid tau in an independent cohort.

This study identified a novel genetic association with resistance to ERC tau deposition in older adults.  Our data also suggests that tau deposition may have a genetic architecture distinct from known AD risk genes, which may have implications for enhanced risk prediction and therapeutic targeting.

Authors/Disclosures
Vijay K. Ramanan, MD, PhD (Mayo Clinic)
PRESENTER
The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. The institution of Dr. Ramanan has received research support from Expert Perspectives in Medicine. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
No disclosure on file
Scott Przybelski Scott Przybelski has nothing to disclose.
Sheela Raghavan No disclosure on file
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Val J. Lowe, MD (Mayo Clinic) Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.
Michelle M. Mielke, PhD (Wake Forest University School of Medicine) Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LabCorp. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens Healthineers. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunbird Bio. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Mielke has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Mielke has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novo Nordisk.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Owen A. Ross, PhD (Mayo Clinic Jacksonville) Dr. Ross has nothing to disclose.
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.